Navigation
banner
Together we Drive the Future

Protease Inhibitors in Drug Discovery

2017-06-292018-01-222017-12-21
EARLY BIRD DISCOUNT! Register by Dec 21, 2017 to receive 20.00% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 speakers list is currently being formed.

Please come back and visit this page for updates.

BELOW IS THE SPEAKERS LIST FROM 2017.

KEYNOTE SPEAKERS
Lawrence R. Dick

Lawrence R. Dick
Director of Biochemistry
Takeda
Lawrence R. Dick
Director of Biochemistry
Takeda
 
About Speaker:

Larry Dick holds a B.S. in biology from Marquette University and earned aPh.D. in biophysics from The University of Texas at Dallas in the laboratory of Professor Donald Gray. He did postdoctoral research at The University of Texas Southwestern Medical Center with Drs. Clive Slaughter and George DeMartino studying the structure and function of the proteasome. He began his industrial career at MyoGenics/ProScript and was part of the team that discovered the first-in-class proteasome inhibitor VELCADE (bortezomib). For the past 19 years he has worked in Discovery at Millennium/Takeda where he was Director of Biochemistry and a member of the teams that discovered the investigational NEDD8 activating enzyme inhibitor, pevonedistat, the investigational ubiquitin activating enzyme inhibitor, TAK-234, and the proteasome inhibitor NINLARO (ixazomib). Currently he is a Scientific Fellow in the Oncology Clinical Research group working on development of UPS-related investigational drugs.

Alfred Goldberg

Alfred Goldberg
Professor of Cell Biology
Harvard Medical School
Alfred Goldberg
Professor of Cell Biology
Harvard Medical School
 
About Speaker:

Dr. Goldberg, a Professor of Cell Biology at Harvard Medical School, has been on the faculty of that institution for nearly his entire academic career. His important discoveries have concerned the biochemical mechanisms and physiological regulation of protein breakdown in cells and the importance of this process in human disease. His laboratory first demonstrated the non-lysosomal ATP-dependent pathway for protein breakdown, now termed the ubiquitin-proteasome pathway. They first demonstrated the involvement of the 20S and 26S proteasomes in this process and discovered the ATP-dependent proteases responsible for protein degradation in bacteria and mitochondria. Also of wide impact have been Dr. Goldberg’s studies showing that the ubiquitin proteasome pathway is critical in the clearance of misfolded proteins and in muscle atrophy seen in many disease states as well as in antigen presentation to the immune system. He and his colleagues also first introduced proteasome inhibitors now widely used as research tools, and he initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now widely used in the treatment of multiple myeloma.

Dr. Goldberg received his AB degree and his PhD in Physiology in 1968 from Harvard University, after attending Cambridge University (as a Churchill Scholar) and Harvard Medical School. Dr. Goldberg’s accomplishments have been recognized with many distinguished prizes, including the Novartis-Drew Award, Severo Ochoa Award (New York University), Knobil Prize for Medical Research (Univ Texas, the Gabbay Award for Biotechnology and Medicine (Brandeis University), Norman Alpert Prize for Medical Research (Harvard), and Earnest Beutler Prize for Basic Research (Amer Hematology Soc.). He is a Fellow of the American Academy of Arts & Sciences and a member of the National Academy of Sciences and the National Institute of Medicine. He has received honorary degrees from Cold Spring Harbor Laboratories, the Univ of Maastricht (Netherlands) and Univ. of Barcelona (Spain) and is among the 1% most cited authors in the life sciences.

Tony Hunter

Tony Hunter
American Cancer Society Professor, Molecular and Cell Biology Laboratory, Renato Dulbecco Chair
Salk Institute
Tony Hunter
American Cancer Society Professor, Molecular and Cell Biology Laboratory, Renato Dulbecco Chair
Salk Institute
 
About Speaker: Tony Hunter is the Renato Dulbecco Chair in Cancer Research, Deputy Director of the Salk Institute Cancer Center and an American Cancer Society Professor in the Molecular and Cell Biology Laboratory at the Salk Institute for Biological Studies in La Jolla. In 1979, through his work on tumor viruses, he discovered a new class of protein kinase that phosphorylates tyrosine. He has spent most of the last 35 years studying protein kinases and phosphatases, and the role of protein phosphorylation in cell proliferation and the cell cycle, and how aberrant protein phosphorylation can cause cancer. His group also works on other types of posttranslational modifications (PTMs), including ubiquitylation and sumoylation, and crosstalk between PTMs. He has received many awards for his work on tyrosine phosphorylation, and is a member of several academic societies including the US National Academy of Sciences and the Royal Society of London.
Marie-Pierre Bousquet-Dubouch

Marie-Pierre Bousquet-Dubouch
Assistant Professor
University of Toulouse
Marie-Pierre Bousquet-Dubouch
Assistant Professor
University of Toulouse
 
About Speaker:

Education:

1994: Engineer in biochemistry from Institut National des Sciences Appliquées de Toulouse (INSAT).

1994: Master degree in Biotechnology - Microbiology, Institut National des Sciences Appliquées de Toulouse (INSAT).

1997 : Ph.D. in Biotechnology, Institut National des Sciences Appliquées de Toulouse (INSAT).

Experience:

1992-1994: Industrial trainee at ZENECA BioProducts (Billingham – England) – 18 months

1994-1997: Ph.D. thesis, Laboratory of Prof. P. MONSAN, Laboratoire d’Ingénierie des Systèmes Biologiques et procédés (LISBP): Enzymatic synthesis of alpha-glucosides derivatives for cosmetic applications. Biocatalysis

1997-1999: Postdoctoral and research engineer positions, Centre Régional d’Innovation et de Transfert de Technologies (CRITT, Toulouse). Industrial research contract with ULICE (LIMAGRAIN group).

1999-2002: Assistant Professor of Biochemistry, Laboratory headed by Prof. M.D. Legoy, Laboratoire de Génie Protéique et Cellulaire (LGPC), University of La Rochelle: Fundamentals of gas/solid biocatalysis and application for enantioselective synthesis of chiral synthons.

Since 2002: Associate Professor of Biochemistry at University of Toulouse 3, Senior research scientist at Institut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse. Research expertise in Proteomics and mass spectrometry of biomolecules, structure-activity relationship of human proteasome complexes, study of protein complexes dynamics by quantitative proteomics, protein posttranslational modifications, targeted proteomics.

Philipp Ottis

Philipp Ottis
Postdoc Associate Lab of Prof. Craig M. Crews Molecuar, Cellular, and Developmental Biology
Yale University
Philipp Ottis
Postdoc Associate Lab of Prof. Craig M. Crews Molecuar, Cellular, and Developmental Biology
Yale University
 
About Speaker:

Philipp Ottis obtained his undergraduate degree in Biology from the University of Cologne, Germany, involving research in analytical natural compounds chemistry. Staying in Cologne, for his Master’s degree, Philipp focused on biochemical studies and research on post-translational protein modification. For his doctoral work, he joined the lab of Carsten Korth at the University of Dusseldorf, Germany, where Philipp studied aberrant protein accumulation associated with proteostasis impairment in brain aging and disease. Amongst other things, his work led to the identification of a previously unknown interaction of two major Schizophrenia risk-factor proteins and the Ziskind-Somerfeld Award of the Society of Biological Psychiatry.

Switching general research fields, yet staying with protein quality control, Philipp currently is a postdoctoral research associate in the group of Craig Crews at Yale University employing the Proteolysis Targeting Chimera (PROTAC) technology to target previously “undruggable” proteins and to study various downstream effects induced by spatio-temporally controlled ubiquitylation.

Eric Strieter

Eric Strieter
Assistant Professor
University of Massachusetts Amherst
Eric Strieter
Assistant Professor
University of Massachusetts Amherst
 
About Speaker:

Eric Strieter is an Assistant Professor in the Departments of Chemistry and Biochemistry and Molecular Biology at the University of Massachusetts-Amherst. Eric received his B.S. degree from the University of Wisconsin-Madison. Eric matriculated at MIT for graduate studies in 2000 and received his Ph.D. in 2005. His thesis work focused on investigating the mechanistic details of palladium- and copper-catalyzed carbon-nitrogen bond forming reactions. He then was an American Cancer Society postdoctoral fellow at Harvard Medical School with Prof. Chris Walsh where he studied natural product biosynthesis. In 2009, he began his independent career as an Assistant Professor at the University of Wisconsin-Madison. In August 2016 he moved his lab to UMass-Amherst where he continues to investigate the chemistry and biology of protein ubiquitylation.

DISTINGUISHED SPEAKERS
Daniel Bachovchin

Daniel Bachovchin
Assistant Member, Chemical Biology
Memorial Sloan Kettering Cancer Center
Daniel Bachovchin
Assistant Member, Chemical Biology
Memorial Sloan Kettering Cancer Center
 
About Speaker:

Daniel Bachovchin, Ph.D., is an Assistant Member in the Chemical Biology Program at Memorial Sloan Kettering Cancer Center. The Bachovchin lab uses chemical biology approaches to study the roles that proteases play in cancer and immune system signaling. Dr. Bachovchin performed graduate research at The Scripps Research Institute with Ben Cravatt and postdoctoral research at The Broad Institute with Todd Golub.

Dieter Brömme

Dieter Brömme
Professor, Canada Research Chair, Oral Biological and Medical Sciences
University of British Columbia
Dieter Brömme
Professor, Canada Research Chair, Oral Biological and Medical Sciences
University of British Columbia
 
About Speaker:

Dieter Brömme is a professor and Canada Research Chair in Proteases and Disease at the Department of Oral Biological and Medical Sciences of the University of British Columbia in Vancouver/Canada. He received his Ph.D. from the Martin-Luther-University (MLU) in Halle(Saale)/GDR in 1983. Since his post-graduate studies at the MLU he carried on his interest in lysosomal cysteine proteases and their role in human pathology throughout his career which included positions at the Biotechnology Research Institute in Montreal, at Khepri/Arris Pharmaceuticals in South San Francisco, and at the Mount Sinai School of Medicine in New York before joining the University of British Columbia.

Antoine Dufour

Antoine Dufour
Postdoctoral Fellow, Chris Overall Lab
University of British Columbia
Antoine Dufour
Postdoctoral Fellow, Chris Overall Lab
University of British Columbia
 
About Speaker:

Antoine Dufour, Ph.D., is a post-doctoral fellow funded by the Canadian Institutes of Health Research (CIHR) in the laboratory of Chris Overall, the pioneer of degradomics, at the University of British Columbia. He received his doctoral degree from Stony Brook University in chemical biology working on the development of exosite inhibitors (patent STONYB-16639) for the inhibition of matrix metalloproteinases during cancer cell migration, invasion, angiogenesis and tumor metastasis. In 2014, Dr. Dufour was the chair of the Gordon Research Seminar “Proteolytic Enzymes & Their Inhibitors” in Il Ciocco, Italy. He currently studies the role of various proteases in immune regulation, viral response, cancer and autoimmune/inflammatory diseases using degradomics and proteomics.

Mark Gorrell

Mark Gorrell
Molecular Hepatology Laboratory Head, Centenary Institute of Cancer Medicine & Cell Biology
University of Sydney
Mark Gorrell
Molecular Hepatology Laboratory Head, Centenary Institute of Cancer Medicine & Cell Biology
University of Sydney
 
About Speaker:

Associate Professor Mark Gorrell of the Centenary Institute, University of Sydney, trained in cell biology, virology, immunology and protein biochemistry at Australian National University, University of Melbourne and Johns Hopkins University. His research is focussed upon liver cancer prevention and treatment, chronic liver disease pathogenesis, diabetes, protein and protease biochemistry and cell biology related to the proteases DPP4, DPP9 and fibroblast activation protein (FAP). He has authored over 130 publications attracting >5,000 citations and H index 38.

Johanna Heideker

Johanna Heideker
PhD
Genentech
Johanna Heideker
PhD
Genentech
 
About Speaker:

Dr. Heideker received her PhD in 2012 from The Scripps Research Institute, La Jolla, CA, studying the functions of a SUMO-targeted ubiquitin ligase in DNA repair and genome maintenance in the laboratory of Michael (Nick) Boddy. From there she joined Ingrid E. Wertz' lab at Genentech as a Postdoctoral researcher, where she set out to explore novel roles of deubiquitinases (DUBs) in human disease. During her time at Genentech in collaboration with the Proteomics and Biostatistics departments she build a novel quantitative platform to measure deubiquitinase activity in a semi-native environment that can be used to both identify new cellular modes of DUB regulation as well as aid the development of compounds targeting DUB activity. Her assay is now being used across GNE departments to aid the study of DUBs and support drug discovery efforts targeting the ubiquitin-proteasome system.

Benedikt Kessler

Benedikt Kessler
Professor of Biochemistry and Life Science Mass Spectrometry
Oxford University
Benedikt Kessler
Professor of Biochemistry and Life Science Mass Spectrometry
Oxford University
 
About Speaker:
Tobias Kromann-Hansen

Tobias Kromann-Hansen
PhD
University of California San Diego
Tobias Kromann-Hansen
PhD
University of California San Diego
 
About Speaker:

Tobias Kromann-Tofting, PhD., is currently a Postdoc at the Department of Chemistry and Biochemistry at University of California San Diego. Tobias Kromann-Tofting received his PhD in Molecular Biology from Aarhus University, Denmark. Tobias Kromann-Tofting’ research is concentrated on the development of inhibitors against trypsin-like serine proteases. Working with the protease urokinase-type plasminogen activator (uPA), which is involved in progression of diseases such as arthritis and cancer, Tobias Kromann-Tofting has developed new principles for intervention with the catalytic activity of uPA by studying a new type of protease inhibitors namely singe domain antibody fragments from Camelids (Alpacas, Camels, Dromedaries and Llamas).

Gang Lin

Gang Lin
Associate Professor of Research in Microbiology and Immunology
Cornell University
Gang Lin
Associate Professor of Research in Microbiology and Immunology
Cornell University
 
About Speaker:

My lab focuses on developing species-selective or isoform-selective proteasome inhibitors for diseases, such as Tuberculosis, malaria, autoimmune and inflammatory disorders.

Rama K. Mallampalli

Rama K. Mallampalli
UPMC Endowed Professor and Division Chief, Pulmonary, Allergy, and Critical Care Medicine
University of Pittsburgh
Rama K. Mallampalli
UPMC Endowed Professor and Division Chief, Pulmonary, Allergy, and Critical Care Medicine
University of Pittsburgh
 
About Speaker:

Dr. Mallampalli is a UPMC Endowed Professor and Division Chief of Pulmonary Allergy, and Critical Care Medicine at the University of Pittsburgh School of Medicine. He work is internationally recognized in the pathogenesis of sepsis and pneumonia as it relates to acute lung injury (ALI). His research has discovered a unique model for the molecular behavior of ubiquitin E3 ligase subunits belonging to the Skp-Cullin1-F box (SCF) family that control inflammation. Dr. Mallampalli’s laboratory designed, synthesized, and tested a new genus of ubiquitin E3 ligase (F box) inhibitors that modulate proteolysis thereby inhibiting inflammation in preclinical models of ALI and multi-organ failure.

Christopher M. Overall

Christopher M. Overall
Canada Research Chair in Protease Proteomics and Systems Biology
Centre for Blood Research, University of British Columbia
Christopher M. Overall
Canada Research Chair in Protease Proteomics and Systems Biology
Centre for Blood Research, University of British Columbia
 
About Speaker:

Dr. Overall is a Professor and Canada Research Chair in Protease Proteomics and Systems Biology, U.B.C. Vancouver. With 23 Nature Review, Science, and Nature/Cell/Science-sister journal papers (h-index 67), he is a pioneer of degradomics, a term he coined. He completed his Ph.D. at the University of Toronto; and post-doctoral work with Dr. Michael Smith, Nobel Laureate. In 1997/1998 was a Visiting Senior Scientist at British Biotech, Oxford and in 2004/2008 a Visiting Senior Scientist at Novartis, Basel, and is now an Honorary Professor, Albert-Ludwigs Universität Freiburg. Dr. Overall was 2002 CIHR Scientist of the Year, the UBC Killam Senior Researcher Award 2005, and was Chair of the 2003 MMP and the 2010 Protease Gordon Research Conferences. He was recognized by the IPS with the 2011 Lifetime Achievement Award; by the Matrix Biology Society of Australia and New Zealand with the 2012 Barry Preston Award; and in 2014 by the Tony Pawson Canadian National Proteomics Network Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community. He is also an elected member of HUPO Executive Committee, the Chromosome Centric Human Proteome Project (C-HPP) Executive Committee, and is an Associate Editor of the Journal of Proteomics Research.

Preety Panwar

Preety Panwar
Research Associate, OBMS
University of British Columbia
Preety Panwar
Research Associate, OBMS
University of British Columbia
 
About Speaker:

Preety Panwar, PhD., is a research associate in Dieter Bromme’s group at University of British Columbia. She has background in liposomes mediated drug delivery. Currently, she is investigating the mechanism of cathepsin K mediated extracellular matrix degradation, and identification of specific anti-collagenase inhibitors of cathepsin K and their in vitro and vivo evaluation.

Maurizio Pellecchia

Maurizio Pellecchia
Professor of Biomedical Sciences Daniel Hays Endowed Chair in Cancer Research
UC Riverside School of Medicine
Maurizio Pellecchia
Professor of Biomedical Sciences Daniel Hays Endowed Chair in Cancer Research
UC Riverside School of Medicine
 
About Speaker:

Dr. Pellecchia is a chemical biologist with a strong background in pharmaceutical chemistry, biophysics and translational medicine. He trained at the University of Naples (Italy) where he obtained a MS in Organic Chemistry and a Ph.D. in Pharmaceutical Sciences, at the ETH-Zurich (working with 2002 Nobel Laureate Prof. Dr. Kurt Wüthrich) and the University of Michigan. Prior to his recruitment in 2002 at the Burnham Institute for Medical Research as Associate Professor, he spent a few years in the pharmaceutical industry. He has served on the faculty of the now Sanford Burnham Prebys medical Discovery Institute for 14 years where he also served as the Associate Director for Translational Research for the Institute’s NCI designated Cancer Center.

Since 2015 he is a Professor of Biomedical Sciences at the University of California at Riverside, School of Medicine and I hold the Daniel Hays endowed Chair in Cancer Research. In addition is the Director of the Center for Molecular and Translational Medicine at UCR. His research is at the forefront of academic drug discovery andchemical biology initiatives. His goals are to support target identification and validation studies in oncology, neurodegenerative, and infectious diseases. The laboratory focuses primarily on the development of innovative pharmacological agents and subsequently apply such agents in target validation studies using cellular and animal models, both internally and via collaborations. Central to these activities are the developing and the application of novel methods and strategies to drug discovery and translational medicine.

Luke Peterson

Luke Peterson
Assistant Research Scientist
University of Michigan
Luke Peterson
Assistant Research Scientist
University of Michigan
 
About Speaker: PhD from the University of Manchester UK,Postdoc The Scripps Research Institute La Jolla, CAUniversity of Michigan since 2007
Guy Salvesen

Guy Salvesen
Professor, Tumor Microenvironment and Cancer Immunology Program
NCI-Designated Cancer Center
Guy Salvesen
Professor, Tumor Microenvironment and Cancer Immunology Program
NCI-Designated Cancer Center
 
About Speaker:
Kvido Strisovsky

Kvido Strisovsky
Principal Investigator
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
Kvido Strisovsky
Principal Investigator
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
 
About Speaker:

Kvido Strisovsky, PhD, is a group leader at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague, Czech Republic. He received education at Charles University, Prague, and at Cambridge University and MRC Laboratory of Molecular Biology, United Kingdom. Dr. Strisovsky studies the mechanism and roles of intramembrane proteolysis in biological regulation. Most notably, he discovered the principles of substrate recognition by rhomboid proteases, his group was the first to solve a structure of an intramembrane protease with a fragment of its substrate and is a pioneer in the development of rhomboid protease inhibitors. Dr. Strisovsky is a member of the EMBO Young Investigator Programme.

Steven Wagner

Steven Wagner
Associate Professor, Neuroscience
University of California San Diego
Steven Wagner
Associate Professor, Neuroscience
University of California San Diego
 
About Speaker:

Dr. Steven Wagner PhD is an Associate Professor in the Department of Neurosciences at UCSD. He has spent over 25 years in the biopharmaceutical industry, and more recently in academia studying translational neuroscience of age-related neurodegenerative disorders with an emphasis on Alzheimer’s disease (AD). He led the team that discovered the first non-NSAID-like and truly “Notch-sparing” gamma-secretase modulators and introduced the term “gamma-secretase modulators” (GSMs) in 2005 through the discovery of a novel series of diaryl-2-aminothiazole derivatives that are over 5000-fold more potent at lowering A42 levels than the NSAID-like “substrate-targeted” gamma-secretase modulators, e.g., tarenflurbil. His team also, for the first time, purified to homogeneity the gamma-secretase enzyme complex that is ultimately responsible for generating amyloid β(Aβ) plaques, the diagnostic hallmark of AD. Since moving back to academia, into the Department of Neurosciences at UCSD in June of 2009, his laboratory, in addition to designing/discovering another novel and structurally distinct GSM chemotype, was awarded a Blueprint Neurotherapeutics U01 by NIH/NINDS (one of only seven issued in all of Neurology) to optimize and develop GSMs for the treatment and/or prevention of AD. He is also a member of the NIH Drug Discovery SBIR (ETTN-M)ETTN IRG, Division of Neuroscience, Development and Aging Study Section, a member of the NINDS Special Emphasis Panel for the Blueprint Neurotherapeutics Network, as well as a member of the Cure Alzheimer’s Fund (CAF) Research Consortium and the Scientific Advisory Board for the Alzheimer’s Association’s Collaboration for Cure (C4C).

PLENARY SPEAKERS
Anne Bang

Anne Bang
Director, Cell Biology
Sanford Burnham Prebys Medical Discovery Institute
Anne Bang
Director, Cell Biology
Sanford Burnham Prebys Medical Discovery Institute
 
About Speaker:

Anne Bang joined the Sanford Burnham Prebys in June 2010 as Director of Cell Biology at the Conrad Prebys Center for Chemical Genomics, a state-of-the-art drug discovery center. Her efforts there are directed at developing patient-specific, and human induced pluripotent stem cell (hiPSC)-based models that reflect higher order cellular functions and disease phenotypes, yet have the throughput and reproducibility required for drug discovery and target identification. Prior to joining SBP she was at ViaCyte Inc. where, as Director of Stem Cell Research, she managed an interdisciplinary group of scientists working to develop hESC as a replenishable source of pancreatic cells for the treatment of diabetes. Dr. Bang has over 20 years of experience in the fields of developmental and stem cell biology, with a focus on neural development. She received a B.S. from Stanford, a Ph.D. in Biology from UCSD, and was a post-doctoral fellow at the Salk Institute.

Michael A. Mancini

Michael A. Mancini
Professor
Baylor College of Medicine
Michael A. Mancini
Professor
Baylor College of Medicine
 
About Speaker:
David Nolte

David Nolte
Distinguished Professor, Physics
Purdue University
David Nolte
Distinguished Professor, Physics
Purdue University
 
About Speaker:

David D. Nolte is the Edward M Purcell Distinguished Professor of Physics and Astronomy at Purdue University performing research in the fields of optical technologies for molecular diagnostics and cancer therapeutics. He received his baccalaureate from Cornell University in 1981, his PhD from the University of California at Berkeley in 1988, and was a post-doctoral member of AT&T Bell Labs before joining the physics faculty at Purdue. He has been elected Fellow of the Optical Society of America, Fellow of the American Physical Society and Fellow of the AAAS. In 2005 he received the Herbert Newby McCoy Award of Purdue University. He has founded two biotech startup companies in the area of diagnostic screening and high-content analysis.

Sofie PattjIn

Sofie PattjIn
CTO
ImmunXperts SA
Sofie PattjIn
CTO
ImmunXperts SA
 
About Speaker:

Sofie Pattijn (CTO and founder, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vacci nes and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNom ics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

Jan de Sonneville

Jan de Sonneville
CEO
Life Science Methods B.V.
Jan de Sonneville
CEO
Life Science Methods B.V.
 
About Speaker:

Born on 14-09-1980 in Amsterdam, the Netherlands. Bachelor in Electrical Engineering, Delft University of Technology (TUDelft), Master in NanoScience (Applied Physics), given as joint program by TUDelft and Leiden University, the Netherlands (2006). PhD on the development of four novel research methods for Cell Biology, thesis title: Reinventing microinjection, new microfluidic methods for cell biology (2011). Founded Life Science Methods BV to sell Automated Microinjection Systems for high throughput screening using cell spheroids and zebrafish embryos (2011).

Chris Wilson

Chris Wilson
Associate Director
Small Molecule Discovery Center, UCSF
Chris Wilson
Associate Director
Small Molecule Discovery Center, UCSF
 
About Speaker:

Chris Wilson is Associate Director of screening at the Small Molecule Discovery Center, UCSF Mission Bay,. He was previously a Senior Scientist at Ensemble Therapeutics (Cambridge, MA) and a postdoctoral fellow at Yale University, in the protein engineering group of Prof. Lynne Regan.

Roland Wolkowicz

Roland Wolkowicz
Professor, Director of the FACS Facility
San Diego State University
Roland Wolkowicz
Professor, Director of the FACS Facility
San Diego State University
 
About Speaker:

Roland Wolkowicz, Ph.D. is a Professor in Biology at San Diego State University in SD, CA. Born in Barcelona, Spain, he pursued undergraduate research in Biology at the University of Tel Aviv, Israel. Obtained his MSc in Microbiology from Tel Aviv University, and PhD in Molecular Cell Biology from the Weizmann Institute of Science in Rehovot, Israel, where he studied the p53 DNA binding activity. As a postdoctoral fellow at Stanford University, he became acquainted with retroviral technology, peptide libraries and flow cytometry-based biological screenings. As a research associate at Stanford, he studied novel ways to block HIV-1 infection. In 2006, he joined the Department of Biology at San Diego State University, where he also serves as the Director of the FACS Core facility. His laboratory investigates viral-host interactions, focusing mainly on HIV-1 and Flaviviridae members such as HCV, Dengue virus, West Nile virus and Zika. His laboratory studies the effect of infection on host signaling cascades, and develops cell-based assays that monitor proteolytic cleavage for drug discovery.